Regenxbio (RGNX) Capital Expenditures (2015 - 2025)

Regenxbio's Capital Expenditures history runs 11 years deep, the most recent figure standing at $2.1 million for Q4 2025.

• In Q4 2025, Capital Expenditures rose 746.39% year-over-year to $2.1 million; the TTM figure through Dec 2025 stood at $2.4 million (up 399.13% YoY), while the FY2025 annual figure was $2.4 million, up 399.13% from the prior year.
• Capital Expenditures for Q4 2025 stood at $2.1 million, down from $2.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $67.1 million in Q3 2021, with the low at -$67.3 million in Q4 2021.
• The 5-year median for Capital Expenditures is $790500.0 (2024), against an average of $112900.0.
• The sharpest annual moves came in 2021 and 2022: Capital Expenditures soared 827.81% in 2021, then slumped 735.03% in 2022.
• Regenxbio's Capital Expenditures stood at -$67.3 million in 2021, then surged by 97.1% to -$2.0 million in 2022, then plunged by 433.74% to -$10.4 million in 2023, then jumped by 96.82% to -$332000.0 in 2024, then surged by 746.39% to $2.1 million in 2025.
• Business Quant data shows RGNX's Capital Expenditures at $2.1 million in Q4 2025, $2.4 million in Q3 2025, and -$3.1 million in Q2 2025.